|
[posting]61252182[/posting]erster earnings-call ever von ADPT! https://seekingalpha.com/article/4285414-adaptive-biotechnol… CEO Chad Robins talking: +++ At Adaptive, our mission is to translate the genetics of the Adaptive immune system into clinical products to transform how diseases are diagnosed and treated. Our approach represents one of the largest clinical applications of next generation sequencing because the Adaptive immune system has a role to play in almost every disease. Additionally, the Adaptive immune system both detects and treats most diseases, including cancer, autoimmune disorders and infectious diseases in exactly the same way. It does this through specialized cells of the Adaptive immune system, T-cells and B-cells that each have receptors on their cell surface called TCRs, or BCRs that act as scanners. +++ Adaptive is harnessing these natural properties of the adaptive immune system to transform the diagnosis and treatment of disease. Well, it is extremely difficult to accurately decipher this massive genetic code. This is exactly what we set out to do almost a decade ago, we have built a platform to read and translate the genetic information held within our adaptive immune systems to develop diagnostics and therapeutics that are personalized and patient specific, validated by hundreds of patents, partners and publications, our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient's immune system and understand precisely how it detects and treats disease in that patient. We capture these insights in our dynamic clinical in the immunoSEQ database. Now with over 30 billion receptors and use them to develop and commercialize diagnostics and therapeutics tailored to each individual patient. Our platform has near term product applications across three business areas, life science research, clinical diagnostics and drug discovery. +++ The breadth of product potential makes immune driven medicine one of the largest global addressable markets in healthcare. We estimate the potential market opportunity for our current pipeline of products to be greater than $48 billion, including research products, clinical diagnostics and cellular therapies. We believe this market will grow over time as clinicians increasingly appreciate the importance of immune medicine to the diagnosis and treatment of disease and as our pipeline of products and services continues to expand. We have already launched two commercial products, one in life science research called immunoSEQ for sequencing immune receptors, and one in clinical diagnostics called clonoSEQ for monitoring minimal residual disease or MRD in select blood cancers, we have invested purposefully in the commercial infrastructure for our first two products which we will leverage to develop and launch our expansive pipeline. |
|
| aus der Diskussion: | Gewinnerbranchen der Jahre 2006 bis 2040 |
| Autor (Datum des Eintrages): | clearasil (14.08.19 14:35:50) |
| Beitrag: | 85,826 von 94,068 (ID:61252551) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |